Trial Profile
Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Icaritin (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Shenogen Biomedical
- 07 Feb 2023 Status changed from recruiting to discontinued.
- 26 Jan 2021 Planned End Date changed from 1 Aug 2019 to 1 Dec 2022.
- 26 Jan 2021 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2022.